Is 2137.HK overvalued or undervalued?

2137.HK currently has a P/E ratio of -3.07. Relative to the sector average of 26.80, this suggests the stock may be undervalued. A higher P/E than peers means investors are paying more for each unit of earnings, often because they expect faster future growth. However, if that growth does not materialize, the stock can appear overvalued. A lower P/E may indicate weaker growth expectations or higher risk, but it can also signal a potential valuation discount.

How can I buy Brii Biosciences Limited stock?

Brii Biosciences Limited trades on HKSE. Investors in Latin America can buy it through international and regional brokerage and investment platforms. You simply need a valid government ID or passport to get started.

Can I buy fractional shares of 2137.HK?

Yes. Through fractional investing, you can invest exactly the amount you want, starting with as little as $1 or $5 USD (depending on what investment platform you use), and own a proportional piece of the company.

Does buying 2137.HK protect my money against local inflation?

Many investors in Latin America buy international stocks like 2137.HK to protect their purchasing power. Because 2137.HK is priced in foreign currency, your investment is tied to a hard currency. If your local currency devalues against the foreign currency, usually USD or Euro, the underlying value of your stock portfolio remains protected from local inflation.

Do I need a foreign bank account or a Visa to buy 2137.HK shares?

No. A common misconception is that you need a foreign bank account or a foreign visa to invest in international stocks. Today, modern investment platforms allow you to fund your account using local bank transfers or local payment methods right from your home country.

Is 2137.HK a suitable investment for my portfolio?

There is no universal answer, since fit depends on your situation, not just the stock. Think about three things: how well 2137.HK diversifies what you already own, whether you can stomach its price swings given your risk tolerance, and how long you plan to stay invested. As a rule, a single stock works best as one piece of a broader asset allocation and with a multi-year time horizon. This is general information, not personalized financial advice.

All stocks2137.HK

Brii Biosciences Limited

HK$0.86+HK$0.02+1.78%

HKSE / HKD

Market cap

HK$620M

P/E

-3.1

EPS (TTM)

HK$-0.03

Dividend yield

0.00%

Beta

1.25

1Y return

-59.62%

Deposit US$200 and get US$50 for freeT&C apply. Your capital is at risk.Invest with

Compare, tap a companyup to 2 at once

Deposit US$200 and get US$50 for freeT&C apply. Your capital is at risk.Invest with

Financials

The numbers behind the company

Revenue vs net income

RevenueNet income

$15M2021

$7M2022

$8M2023

$7M2024

$3M2025

Financial health

Gross margin

Operating margin

ROE

ROA

Debt to equity0.00Low
Current ratio52.24
Cash ratio14.77
Net margin-918.1%
Free cash flow—

Valuation

Is it expensive right now

P/E vs the market

scale 0–50

0153050

2137.HK-3.1
Healthcare sector median26.8
S&P 50022.0

Trades about 111% below its sector, cheaper than its peers on earnings.

Ratios

PEG-0.04
Price to book0.24
EPS (TTM)HK$-0.03
Payout ratio0%
FCF yield-31.55%

Range & risk

HK$0.81HK$2.01

Trading in the lower third of its 52-week band

Beta1.25

Profile

What Brii Biosciences Limited actually does

Founded in Beijing, China, in 2017, Brii Biosciences Limited is a biopharmaceutical firm dedicated to discovering and developing innovative therapies for infectious diseases and central nervous system disorders. Its diverse pipeline features: early-stage (Phase 1) compounds BRII-778 and BRII-732 for treating HIV; a multifaceted approach to Hepatitis B (HBV) including a Phase 2 combination study of BRII-179 and BRII-835, with BRII-179 (a recombinant protein-based immunotherapeutic) also in Phase 1b/2a, and BRII-835 having successfully completed Phase 2 for chronic HBV patients. The company also offers the Amubarvimab/romlusevimab combination as a treatment for COVID-19. Beyond these, Brii Biosciences is advancing BRII-296 for PPD and BRII-297 for various depressive conditions, alongside several agents targeting highly resistant infections: BRII-636, BRII-672, and BRII-693 are designed to combat multi-drug and extensively drug-resistant (MDR/XDR) gram-negative bacteria, while BRII-658 is under development for MDR/XDR tuberculosis and non-tuberculosis mycobacterial infections.

CEO

Zhi Hong

Employees

Headquarters

Beijing, BE

Founded

2021-07-13

Company website

If you had invested a decade ago

Loading the full price history…

Run your own numbers

Past performance is not a forecast.

ETFs

Own it inside an ETF instead

Vanguard S&P 500

Vanguard Total Stock Market

Vanguard Total World Stock

Invesco QQQ

SPDR S&P 500

iShares Russell 2000

Community sentiment

Bullish—

Distribution

Bearish0%
Neutral0%
Bullish0%

Track it without buyingTrack it

no account needed

Save 2137.HK and get told when something moves.

Get updates

A clear, direct weekly summary.

Keep looking

Q&A

Questions people ask

2137.HK has a beta of 1.25, which indicates how sensitive it has historically been to movements in its broader market. A beta above 1 suggests higher relative volatility than the market. Beta is based on historical data and does not predict future performance.

Brii Biosciences Limited